IOVA: financial statements from SEC — TradeAlmanac

IOVA

Iovance Biotherapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	264m	164m
Cost of revenue	173m	93m
Research and development	300m	276m
Selling, general and administrative	152m	152m
Operating expenses	667m	559m
Operating income	−403m	−395m
Pre-tax income	−393m	−375m
Income tax	−2m	−3m
Net income	−391m	−372m
Earnings per share	−1.09	−1.28
Earnings per share, diluted	−1.09	−1.28
Weighted average shares	357,345	289,877
Weighted average shares, diluted	357,345	289,877

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	197m	163m	158m	132m	172m	116m	164m	229m
Short-term investments	117m	134m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	−302m	−353m
Depreciation and amortisation	13m	11m
Share-based compensation	62m	110m
Capital expenditure	34m	11m
Investing cash flow	47m	−96m
Financing cash flow	301m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)